EXVASTAT
Exvastat is an innovative, preclinical-stage pharmaceutical company founded in 2016. The company is developing a treatment for acute respiratory distress syndrome (ARDS) based on a repurposed drug which is marketed worldwide for other indications. The new treatment has the potential to significantly reduce the high mortality and incapacitating morbidities caused by ARDS, as well as the costs of caring for these critically ill patients to health service providers.
EXVASTAT
Industry:
Biotechnology Health Care Life Science Medical Pharmaceutical
Founded:
2016-01-01
Address:
Cambridge, Cambridgeshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.exvastat.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
3.9 M USD
Technology used in webpage:
SPF Euro Microsoft Exchange Online Office 365 Mail Google Apps For Business Cloudflare JS CDN JS Pexels Twitter CDN WordPress 5.5
Current Advisors List
Current Employees Featured
Founder
Investors List
Innovative Medicines Initiative
Innovative Medicines Initiative investment in Grant - Exvastat
Cambridge Innovation Capital
Cambridge Innovation Capital investment in Seed Round - Exvastat
Official Site Inspections
http://www.exvastat.com
- Host name: af1f69020f2387294.awsglobalaccelerator.com
- IP address: 15.197.212.58
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Exvastat"
Home - Exvastat
ARDS (Acute Respiratory Distress Syndrome) is a severe, life-threatening medical condition characterized by widespread inflammation and fluid accumulation in the lungs. Every year, this condition kills more people than …See details»
About us - Exvastat
Exvastat Ltd have been supported by investment from Cambridge Innovation Capital, who invest in intellectual property rich companies from the University of Cambridge and the wider …See details»
Exvastat - Crunchbase Company Profile & Funding
Organization. Exvastat . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Exvastat is an innovative, preclinical-stage …See details»
Exvastat - Overview, News & Similar companies | ZoomInfo.com
May 14, 2020 Exvastat Ltd is a single asset biopharmaceutical company established in 2016 with investment from Cambridge Innovation Capital (CIC). The founders, Drs. David Cavalla …See details»
Exvastat 2025 Company Profile: Valuation, Funding & Investors
Exvastat General Information Description. Developer of respiratory distress drugs intended to help healthcare providers cure acute respiratory distress syndrome. The company's drugs can …See details»
Exvastat - Org Chart, Teams, Culture & Jobs - The Org
View Exvastat's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Exvastat - Funding, Financials, Valuation & Investors - Crunchbase
Exvastat is an innovative, preclinical-stage pharmaceutical company. How much funding has this organization raised over time? ShowSee details»
Exvastat - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Exvastat . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies ... Member and Advisor Profiles 1. Contacts 1. About. …See details»
Exvastat Company Profile - Office Locations, Competitors ... - Craft
Exvastat has 5 employees across 2 locations and $3.89 m in total funding,. See insights on Exvastat including office locations, competitors, revenue, financials, executives, subsidiaries …See details»
Exvastat - VentureRadar
Exvastat is an innovative, clinical-stage pharmaceutical company founded in 2016. The company is developing a treatment for acute respiratory distress syndrome (ARDS) based on a …See details»
Exvastat - LinkedIn
Exvastat is an innovative, preclinical-stage pharmaceutical company founded in 2016. The company is developing a treatment for acute respiratory distress syndrome (ARDS) based on …See details»
Exvastat - 2025 Company Profile - Tracxn
Mar 6, 2025 Exvastat - Developer of repurposed drug for acute respiratory distress syndrome. Raised a total funding of $2.95M over 5 rounds from 12 investors. Valued at $41.4M. Exvastat …See details»
Exvastat Overview | SignalHire Company Profile
Exvastat is a private company that has been in the industry for 7 years. The company currently specializes in the Pharmaceuticals area. The position of the CEO is occupied by David …See details»
EXVASTAT LTD Company Profile - Dun & Bradstreet
Exvastat ltd. d&b business directory home / business directory / professional, scientific, and technical services / scientific research and development services / united kingdom / …See details»
Exvastat - Products, Competitors, Financials, Employees, …
May 22, 2020 Exvastat's innovation addresses the unmet medical need for an approved pharmacotherapy for ARDS, which is caused by conditions such as pneumonia, sepsis, and …See details»
Exvastat CEO and Key Executive Team | Craft.co
Exvastat's key executives include David Cavalla and 2 others. David Cavalla. CEO. Julia Jones. Director of Finance. Robert Tansley. Chairman. Source: exvastat.com. Report incorrect …See details»
Appointment of Dr Julian Gilbert as Non-Executive Director
Cambridge, UK [26th April 2021]: Exvastat Limited is pleased to announce the appointment of Dr Julian Gilbert to its Board as a Non-Executive Director. Julian has more than 30 years of …See details»
Further investment and three new appointments announced
Exvastat is a clinical stage company developing intravenous imatinib (Impentri™) as a first-in-class pharmacotherapy for all-cause ARDS and COVID-19 pneumonia to lower mortality and …See details»
Exvastat - Tech Stack, Apps, Patents & Trademarks - Crunchbase
The intellectual property of Exvastat includes 2 registered patents primarily in the ' Medical Or Veterinary Science; Hygiene ' category, according to IPqwery. Additionally, Exvastat has 1 …See details»
☑️Exvastat Ltd — Consulting Organization from UK, experience …
Exvastat Ltd — Consulting Organization from UK, has experience with Horizon 2020 (2014 - 2020), it`s involved in Health, Research sectors. Our website uses cookies to enable essential …See details»